Researchers have developed a new and improved viral vector -- a virus-based vehicle that delivers therapeutic genes -- for use in gene therapy for sickle cell disease. In advanced lab tests using ...

Please use one of the following formats to cite this article in your essay, paper or report: APA. Robertson, Sally. (2019, October 03). Novel viral vector improves gene therapy for sickle cell ...

About LYFGENIA™ LYFGENIA is a one-time ex-vivo lentiviral vector gene therapy approved for the treatment of patients 12 years of age or older with sickle cell disease and a history of vaso ...

The company shut down its trials for sickle cell patients and those with another blood disorder, ... “These data indeed point away from the vector as causative,” he wrote in an email.

A panel of experts said on Tuesday that a groundbreaking treatment for sickle cell disease was safe enough for clinical use, setting the stage for likely federal approval by Dec. 8 of a powerful ...

Sickle-cell is caused by inheriting two bad copies of one of the genes that make hemoglobin. Symptoms include bouts of intense pain, and life expectancy with the disease is just 53 years.